Le Lézard
Classified in: Health, Science and technology
Subjects: Photo/Multimedia, Award

bit.bio Celebrates Double Award Win at Cambridge Science and Technology Awards 2022 Including Biotech of the Year for the Second Time in a Row

Members of the bit.bio were celebrating last week to mark their double win at the Cambridge Independent Science and Technology Awards this month.

At the ceremony on Wednesday 11 May in Cambridge, the company took home the Biotech of the Year Award for the second time in a row. And the CEO and founder Dr Mark Kotter was awarded CEO of the Year.

The shortlist and competition for Biotech of the Year was described by the organisers as "extremely fierce" and there were eight finalists on the shortlist for the CEO award.

Addressing employees at the celebration, held in bit.bio's offices last week, Mark Kotter said:

"This achievement is a testimony to the bit.bio team. This is your award. Thank you for all your hard work and the transformational technology you are translating into products and new therapies."

Accepting the awards at the ceremony, Chief Corporate Officer Florian Schuster said:

"It's a real honour to take home Biotech of the Year again and to see Mark awarded CEO of the Year. Hearing the shortlist at the ceremony makes you realise how full of talent and innovation Cambridge is. It was a privilege to be in such good company in person and to celebrate what's been a huge year of growth for bit.bio."

The awards ceremony began with a networking reception before the awards were handed out in the Francis Crick Auditorium, attended by around 250 business leaders, entrepreneurs and scientists.

Editor Paul Brackley, who hosted the event and chaired the judging panel, said:

"The judging panel had a very challenging task selecting the winners from the record number of entries we had for our fifth annual awards, and it was terrific to showcase all of our finalists."

The full shortlists for the awards that bit.bio won were:

Biotech Company of the Year

CEO of the Year

Notes to Editors

About bit.bio
bit.bio combines the concepts of coding and biology to provide human cells for research, drug discovery and cell therapy, enabling a new generation of medicines.

This is possible with our precision cellular reprogramming technology, opti-oxtm - a breakthrough gene engineering approach that enables unlimited batches of any human cell to be manufactured consistently at scale through direct reprogramming of stem cells.

bit.bio was founded in 2016 by Dr Mark Kotter from his labs at Cambridge University after his discovery of the opti-ox technology. Co-founder Florian Schuster joined in 2018 as the company continued to grow and develop.

The company now has over 130 employees and is headquartered in Cambridge, UK and San Francisco, US.

These press releases may also interest you

at 12:30
New data presented in two separate oral presentations at the European Association for the Study of the Liver's International Liver Congress 2022 (EASL ILC 2022)Following 90 days of dosing, ATI-2173, in combination with tenofovir disoproxil fumarate...

at 11:54
With its ruling today, the U.S. Supreme Court has overturned Roe v. Wade, dismantling the constitutional right to abortion that has stood for nearly 50 years. Roe is overturned at a time when 26 states are poised to ban abortion which will leave 36...

at 11:22
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Apyx Medical Corporation between May 12, 2021 and March 11, 2022, both dates inclusive (the "Class Period"), of the important August 5, 2022 lead...

at 09:05
Ionis Pharmaceuticals, Inc. , today...

at 04:05
AB-729, our RNAi therapeutic, provided robust and comparable HBsAg declines in both HBeAg+ and HBeAg- patients 50% (16 out of 32) of patients maintained HBsAg levels below 100 IU/mL 24 weeks after their last AB-729 dose In the first five patients...

at 00:35
Sinovac Biotech Ltd. ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that the South African Health Products Regulatory Authority (SAHPRA) granted conditional registration to SINOVAC CoronaVac®...

News published on 23 may 2022 at 08:30 and distributed by: